论文部分内容阅读
应用正交试验对影响ＬＩＣＣ的生成及其杀伤较大的因素（诱导时间，ＩＬ－２浓度，细胞毒细胞分化因子－ＣＣＤＦ，效应细胞与靶细胞的比例）进行筛选，以获得高杀伤活性的ＬＩＣＣ。对荷瘤动物分组用毛细管法进行白细胞移动抑制试验（ＭＩＴ），在Ｈ＿２２攻击后的第５周、第７周ＬＩＣＣ实验动物的ＭＩＴ阳性率明显高于对照组，其差异有显著性（Ｐ＜０．０５），提示ＬＩＣＣ能维持或提高机体对Ｈ＿２２的特异性细胞免疫功能。同时，实验组动物死亡率明显低于对照组，荷瘤存活时间较对照组也明显延长，提示ＬＩＣＣ对荷瘤动物有保护作用。是继ＬＡＫ细胞、ＴＩＬ细胞之后的又一种新型的肿瘤过继性免疫治疗细胞。
Orthogonal test was used to screen the factors affecting the production of LICC and its greater killing (induction time, IL-2 concentration, cytotoxic differentiation factor-CCDF, ratio of effector cells to target cells) to obtain high killing activity LICC. The leukocyte migration inhibition test (MIT) was carried out on tumor-bearing animals by capillary method. The positive rate of MIT in LICC animals was significantly higher than that of the control group on the 5th and 7th week after H22 challenge (P<0.05). 0.05), suggesting that LICC can maintain or increase the body’s specific cellular immune function to H_22. At the same time, the animal mortality rate in the experimental group was significantly lower than that in the control group, and the tumor-bearing survival time was also significantly longer than that in the control group, suggesting that LICC has a protective effect on tumor-bearing animals. It is a new type of tumor adoptive immunotherapy cells following LAK cells and TIL cells.